NCT00878163View on ClinicalTrials.gov

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

January 22, 2013

Study Completion Date

March 6, 2026

Conditions
Adult Solid NeoplasmPancreatic Acinar Cell CarcinomaPancreatic Ductal AdenocarcinomaRecurrent Pancreatic CarcinomaStage IV Pancreatic Cancer AJCC v6 and v7
Interventions
OTHER

Diagnostic Laboratory Biomarker Analysis

Correlative studies

DRUG

Erlotinib Hydrochloride

Given PO

DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Vismodegib

Given PO

Trial Locations (4)

32806

Orlando Health Cancer Institute, Orlando

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH